RUMENSIN CRC DIN 02082128
Health Canada record
| Active ingredient(s) | MONENSIN (MONENSIN SODIUM) 32 G |
|---|---|
| Dosage form | Capsule (Extended-Release) |
| Route | Oral |
| Schedule | NON-PRESCRIPTION DRUGS |
| Class | Veterinary |
| ATC | |
| Original market date | 31-Dec-1994 |
| Current status date | 19-Jul-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Elanco Canada Limited — licence 102236, currently licensed, last inspection rating C (2022-08-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MONENSIN (MONENSIN SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02231172 | COBAN PREMIX | ELANCO CANADA LIMITED | Drug Premix | MONENSIN (MONENSIN SODIUM) 200 G | Marketed |
| 02451999 | KEXXTONE | ELANCO CANADA LIMITED | Capsule | MONENSIN (MONENSIN SODIUM) 32.4 G | Marketed |
| 02243232 | MONENSIN PREMIX | BIO AGRI MIX LP | Drug Premix | MONENSIN (MONENSIN SODIUM) 200 G | Marketed |
| 02516772 | MONOVET | HUVEPHARMA EOOD | Drug Premix | MONENSIN (MONENSIN SODIUM) 200 G | Marketed |
| 02231173 | RUMENSIN PREMIX | ELANCO CANADA LIMITED | Drug Premix | MONENSIN (MONENSIN SODIUM) 200 G | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 20359 | 2018-01-18 | New Drug Submission (NDS) | MERGER - BUYOUT |
| 11285 | 2010-04-22 | Supplement to a New Drug Submission (SNDS) | Additional claim |
| 10405 | 2009-07-20 | Supplement to a New Drug Submission (SNDS) | Additional warning statement |
| 10086 | 2009-03-11 | Supplement to a New Drug Submission (SNDS) | New capsule design |
| 9681 | 2008-07-16 | Supplement to a New Drug Submission (SNDS) | ADDITIONAL CLAIM |
| 3647 | 2004-02-20 | New Drug Submission (NDS) | |
| 6505 | 2000-02-02 | Supplement to a New Drug Submission (SNDS) | AS AN AID IN THE PREVENTION OF COCCIDIOSIS CAUSED BY EIMERIA ZUERNII AND E. BOVIS IN CATTLE WEIGHING UP TO 350KG |
| 6825 | 1997-11-24 | Supplement to a New Drug Submission (SNDS) | NEW INDICATION |
| 7502 | 1994-03-25 | New Drug Submission (NDS) |